US EditionPublished • loading... • Updated
Larimar Reports Positive Long-Term Data on Nomlabofusp in Friedreich’s Ataxia
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Larimar Reports Positive Long-Term Data on Nomlabofusp in Friedreich’s Ataxia
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) reported new long-term open-label (OL) data for nomlabofusp in Friedreich’s ataxia (FA), showing sustained increases in frataxin (FXN) protein and consistent directional improvements across four clinical outcomes, alongside a revised starting-dose regimen and an accelerated-approval BLA timeline for Q2 2026. As of August 27, 2025, 39 participants in the OL study had received at least on…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
